Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models

Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models

Background Recent preclinical and clinical data suggest that leukemia inhibitory factor (LIF) is a potential target for various tumor types including pancreatic ductal adenocarcinoma as LIF is involved in multiple protumor processes including cancer stem cell maintenance, epithelial–mesenchymal tran...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Ye, Brian A Belt, Shuyang S Qin, Rachel Jewell, Laura M Calvi, Bradley N Mills, Tara G Vrooman, Carl J Johnston, Scott A Gerber, Angela L Hughson, Gary Hannon, Maggie L Lesch, Jim Eyles, Nadia Luheshi, Noah A Salama, Sidney Lesser, Sarah L Eckl, Lauren Benoodt, Edith Lord, David Linehan
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e010820.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e010820.full

Similar Items